Researchers from the Wilmer Eye Institute, Johns Hopkins Medicine Center for Nanomedicine — which designs ...

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

The Company enters 2026 with Multiple Phase 2 Catalysts, AI-enabled drug development strategy, and regulatory optionality as ...

The Nanoparticle Contract Manufacturing market offers opportunities in pharmaceuticals, biotech, and advanced materials, ...

Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b ...

The experimental mRNA-based drug sharply reduced the risk of recurrence or death when combined with immunotherapy Keytruda, ...

The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...

Moderna (MRNA) stock is in focus as the mRNA-based cancer drug with Merck's (MRK) Keytruda cut melanoma recurrence/death risk ...

Researchers from the Wilmer Eye Institute, Johns Hopkins Medicine Center for Nanomedicine—which designs nanotechnology-based ...

A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...